高珊珊;曹礼慧;冯崇廉;袁中文;
GAO Shanshan;CAO Lihui;FENG Chonglian;YUAN Zhongwen;The Third Affiliated Hospital of Guangzhou Medical University;

• 1:广州医科大学附属第三医院

摘要(Abstract)：

目的分析近5年本院名老中医冯崇廉主任治疗脂肪肝的用药规律,对核心药对进行网络药理学分析,探究治疗脂肪肝的机制与靶点,为解释临床疗效提供参考依据。方法检索本院2014年1月～2018年12月冯崇廉主任所开具治疗脂肪肝的中医处方,统计药物使用频次及所属类别,使用SPSS 26.0软件进行聚类分析,并利用网络药理学技术分析特征性药对的成分、靶点及作用机制。结果经筛选得处方共计2 181首,药物188味,药物总使用频次23 804次。使用频次前3位的药物为甘草、枳壳、茯苓等,药对包括半夏-竹茹、蒺藜-蔓荆子等。网络药理学分析表明蒺藜-蔓荆子药对治疗脂肪肝有83个靶点,主要活性成分包括木犀草素、山萘酚、槲皮素等,关键靶点是CCL2、TNF、VCAM1等,主要的作用通路包含血流剪切应力和动脉粥样硬化通路、白细胞介素-17信号通路等。结论本研究总结了冯崇廉主任治疗脂肪肝的用药规律,并以蒺藜-蔓荆子药对为代表探讨其药效机制,为临床治疗提供数据支持。
OBJECTIVE To analyze the rule of drug use in the treatment of fatty liver by Feng Chonglian, a famous old TCM doctor in our hospital in the past five years, and to conduct network pharmacology analysis on the core drug pairs, so as to explore the mechanism and target of the treatment of fatty liver, and to provide reference for the interpretation of clinical efficacy. METHODS traditional Chinese medicine prescriptions for the treatment of fatty liver issued by Director Feng Chonglian in our hospital from January 2014 to December 2018 were retrieved, and the frequency and category of drug use were counted. SPSS 26.0 software was used for cluster analysis. Finally, network pharmacology technology was used to analyze the composition, target and mechanism of action of characteristic drug pairs. RESULTS A total of 2 181 prescriptions, 188 flavors of drugs and 23 804 times of drug use were obtained. The top 3 drugs of use frequency were liquorice, fructusaurantii, poriacocos, And the drug pairs included Pinelliaternata-bamboo shavings, thistle-Fructuscraniae, etc. The pharmacological analysis of the network showed that there were 83 targets for the treatment of fatty liver with thistle and spirochaeta, and the main active components included luteolin, kathoxygenol, quercetin, etc. The key targets were CCL2, TNF, and VCAM1, etc. The main action pathways includedfluid shear stress and atherosclerosis, IL-17 signaling pathwayand so on. CONCLUSION This study summarizes the drug use rule of Director Feng Chonglian in the treatment of fatty liver, and discusses the pharmacodynamic mechanism of the drug pairs of tribulusterebium and fructusfordii for providing data support for clinical treatment.

关键词(KeyWords)： 脂肪肝;用药规律;聚类;网络药理学
fatty liver disease;medication rules;clustering;network pharmacology

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金(81803689);; 广东省自然科学基金项目(2018A030310292);; 广州市中医药和中西医结合科技项目(20202A010013)

作者(Authors): 高珊珊;曹礼慧;冯崇廉;袁中文;
GAO Shanshan;CAO Lihui;FENG Chonglian;YUAN Zhongwen;The Third Affiliated Hospital of Guangzhou Medical University;

参考文献(References)：

• [1] 梁扩寰，李绍白.肝脏病学[M].2版.北京：人民卫生出版社，2003:12.
• [2] 丁静，张斌，王培劼，等.基于数据挖掘和生物信息分析探讨非酒精性脂肪肝用药规律及作用机制[J].中国中药杂志，2019,44(8):1689-1695.
• [3] 高学敏.中药学[M].北京：中国中医药出版社，2002.
• [4] 国家药典委员会.中华人民共和国药典临床用药须知[M].北京：中国医药科技，2010.
• [5] 国家药典委员会.中华人民共和国药典[M].北京：中国医药科技出版社，2015.
• [6]广东省中药材标准编辑委员会.广东省中药材标准[M].广州：广东科技出版社，2004.
• [7] 广东省食品药品监督管理局.广东省中药饮片炮制规范-第一册[M].广州：广东科技出版社，2011.
• [8] Ru J,Li P,Wang J,et al.TCMSP:a database of systems pharmacology for drug discovery from herbal medicines[J].J Cheminform,2014,6:13.
• [9] Shannon P,Markiel A,Ozier O,et al.Cytoscape:a software environment for integrated models of biomolecular interaction networks[J].Genome Res,2003,13(11):2498-2504.
• [10] Zhou Y,Zhou B,Pache L,et al.Metascape provides a biologist-oriented resource for the analysis of systems-level datasets[J].Nat Commun,2019,10(1):1523.
• [11] 余钦，赵沙沙，王婉先，等.甘枣宁治疗非酒精性脂肪性肝病的网络药理学机制[J].广州中医药大学学报，2020,37(4):691-699.
• [12] 杨钦河，凌家生，吴伟康.中医药治疗脂肪肝的用药规律分析[J].中华中医药杂志，2005,20(9):525-527.
• [13] 黄凯文，刘若轩，谢妙金，等.鸡骨草提取物对非酒精性脂肪肝大鼠肝细胞TLR4/p38MAPK信号通路作用[J].广东药科大学学报，2017,33(4):493-497.
• [14] Donaldson J,Ngema M,Nkomozepi P,et al.Quercetin administration post-weaning attenuates high-fructose,high-cholesterol diet-induced hepatic steatosis in growing,female,Sprague Dawley rat pups[J].JSci Food Agric,2019,99(15):6954-6961.
• [15]Xu Y,Han J,Dong J,et al.Metabolomics Characterizes the effects and mechanisms of quercetin in nonalcoholic fatty liver disease development[J].Int J Mol Sci,2019,20(5):E1220.
• [16] Li H,Kim U H,Yoon J H,et al.Suppression of hyperglycemia and hepatic steatosis by black-soybean-leaf extract via enhanced adiponectin-receptor signaling and AMPK activation[J].J Agric Food Chem,2019,67(1):90-101.
• [17] Palma-Duran S A,Kontogianni M D,Vlassopoulos A,et al.Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-,sex- and BMI-matched normo-glycemic adults[J].Metabolism,2018,83:120-127.
• [18] Leung C,Herath C B,Jia Z,et al.Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease[J].World J Gastroenterol,2016,22(35):8026-8040.